Literature DB >> 12883491

Validation and refinement of survival models for liver retransplantation.

Hugo R Rosen1, Martin Prieto, Teresa Casanovas-Taltavull, Valentin Cuervas-Mons, Olaf Guckelberger, Paolo Muiesan, Russell W Strong, Wolf O Bechstein, John O'grady, Atif Zaman, Benjamin Chan, Joaquin Berenguer, Roger Williams, Nigel Heaton, Peter Neuhaus.   

Abstract

Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P <.0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P =.004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model chi(2) = 105, P <.0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.

Entities:  

Mesh:

Year:  2003        PMID: 12883491     DOI: 10.1053/jhep.2003.50328

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Impact of MELD on waitlist outcome of retransplant candidates.

Authors:  H J Kim; J J Larson; Y S Lim; W R Kim; R A Pedersen; T M Therneau; C B Rosen
Journal:  Am J Transplant       Date:  2010-11-10       Impact factor: 8.086

2.  Futility and rationing in liver retransplantation: when and how can we say no?

Authors:  Scott W Biggins
Journal:  J Hepatol       Date:  2012-02-04       Impact factor: 25.083

3.  Liver retransplantation in adults: a single-centre, 25-year experience.

Authors:  Ravi Marudanayagam; Vivekanandan Shanmugam; Bynvant Sandhu; Bridget K Gunson; Darius F Mirza; David Mayer; John Buckels; Simon R Bramhall
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

4.  Short- and long-term outcomes of third liver transplantation at single centre.

Authors:  Hideya Kamei; Mamoun Al-Basheer; Jeffrey Shum; Michael Bloch; Roberto Hernandez Alejandro; Vivian McAlister; William Wall; Douglas Quan
Journal:  Hepatol Int       Date:  2012-03-14       Impact factor: 6.047

5.  Outcomes of liver retransplantation in patients with primary sclerosing cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Lindsay Y King; Jiayin Zheng; Shein-Chung Chow; Andrew J Muir
Journal:  Liver Transpl       Date:  2017-06       Impact factor: 5.799

6.  Waiting list mortality among children listed for heart transplantation in the United States.

Authors:  Christopher S D Almond; Ravi R Thiagarajan; Gary E Piercey; Kimberlee Gauvreau; Elizabeth D Blume; Heather J Bastardi; Francis Fynn-Thompson; T P Singh
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

7.  Effects of graft quality on non-urgent liver retransplantation survival: should we avoid high-risk donors?

Authors:  Josep Marti; Josep Fuster; Miquel Navasa; Joana Ferrer; Antoni Rimola; Amalia Pelegrina; Constantino Fondevila; Juan Carlos Garcia-Valdecasas
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

Review 8.  Management of hepatitis C infection after liver transplantation.

Authors:  Mazen Alsatie; Naga Chalasani; Paul Y Kwo
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Liver transplantation and hepatitis C.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Int J Hepatol       Date:  2012-07-26

10.  Study of re-transplantation and prognosis in liver transplant center in Iran.

Authors:  Javad Salimi; Ali Jafarian; Nasir Fakhar; Alireza Ramandi; Mohamad Behzadi; Ali Moeni; Habib Dashti; Atabak Najafi; Mohammad Reza Shariat; Jalil Makarem; Abdolhamid Chavoshi Khamneh
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.